Hemostemix (CVE:HEM) Stock Price Up 40%
Hemostemix Inc (CVE:HEM) shares rose 40% during trading on Wednesday . The stock traded as high as C$0.04 and last traded at C$0.04, approximately 98,100 shares traded hands during trading. An increase of 20% from the average daily volume of 81,762 shares. The stock had previously closed at C$0.03.
The company has a 50 day simple moving average of C$0.03 and a 200 day simple moving average of C$0.05. The stock has a market capitalization of $7.52 million and a PE ratio of -1.67.
About Hemostemix (CVE:HEM)
Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.
Featured Story: How to Trade Using Analysts Ratings
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.